Key Takeaways
- On April 14, two board members at Conagra purchased 42,500 shares collectively, investing approximately $609,000 as the stock traded close to its lowest point in twelve months.
- Shares of CAG have declined 17% during 2026, pressured by weakening sales volumes, compressed margins, and reduced fiscal guidance.
- Third-quarter results showed earnings per share of $0.39, below the $0.40 estimate, while revenues decreased 1.9% compared to the prior year.
- Morgan Stanley reduced its price objective to $15 from $17 this Thursday while maintaining an “equal weight” stance.
- The consensus rating among analysts stands at “Reduce” with a mean price target of $15.80, based on 1 Buy, 13 Hold, and 4 Sell recommendations.
Two members of Conagra’s board recently made significant personal investments in the company. Richard H. Lenny, a director, acquired 25,000 shares at $14.34 per unit on April 14, totaling $358,500. Fellow director John J. Mulligan purchased 17,500 shares at $14.31 on the same date, amounting to $250,425.
The total investment of approximately $609,000 occurred while shares traded near their 12-month nadir of $14.04. Mulligan’s transaction increased his stake in the company by 542%. Following his purchase, Lenny’s holdings reached 229,340 units with an estimated value of $3.3 million.
The context surrounding these purchases is significant. CAG’s recent decline accelerated on April 9 following a BNP Paribas downgrade from Outperform to Neutral, accompanied by a price target reduction to $16 from $19. The stock closed beneath $16 that day.
The challenges intensified shortly after. Conagra announced John Brase as its incoming CEO and president on April 13. Jefferies noted that Brase would inherit “high leverage, ongoing inflationary pressures, and margin compression.”
Disappointing Quarterly Results
Earlier in April, Conagra released third-quarter fiscal results that fell short of market expectations. The company delivered earnings per share of $0.39, trailing the consensus estimate of $0.40 by one cent. Revenue reached $2.79 billion, marginally exceeding the $2.76 billion forecast.
The modest revenue beat failed to offset broader concerns. Top-line figures declined 1.9% year-over-year, while the company posted $0.51 EPS in the corresponding quarter last year—representing a substantial contraction. Conagra lowered its full-year fiscal outlook, citing challenging macroeconomic conditions and sustained inflationary pressures.
Year-to-date, the stock has fallen 17%. During the same timeframe, the S&P 500 has gained 4.2%.
Wall Street Maintains Reserved Outlook
Analyst sentiment remains guarded toward the stock. Morgan Stanley revised its price target downward to $15 from $17 on Thursday while keeping an “equal weight” rating. This projection suggests only 3.6% potential upside from Wednesday’s closing price.
Morgan Stanley joined several other firms in adjusting expectations. JPMorgan lowered its target from $19 to $17 during March. TD Cowen and Deutsche Bank both set their targets at $14. Stifel reduced its objective to $15 this week.
According to MarketBeat’s current analyst compilation, CAG carries 1 Buy, 13 Hold, and 4 Sell ratings, with a mean price target of $15.80 and an overall “Reduce” rating.
Shares opened Thursday trading at $14.49. The 50-day moving average stands at $16.75, while the 200-day moving average sits at $17.38—both considerably above the current trading level.
A notable metric: CAG presently offers approximately a 9% dividend yield, representing the highest yield among all S&P 500 constituents. The typical dividend yield for income-generating stocks in the index averages 2.3%.
Institutional ownership accounts for 83.75% of outstanding shares. Multiple smaller investment funds expanded their positions during recent quarters, though the additions were relatively limited in scale.
